Fact-checked by Grok 2 weeks ago

Paregoric


Paregoric, also known as camphorated of , is an opioid-containing pharmaceutical preparation primarily used to treat by slowing and intestinal . Its active ingredient is anhydrous at 2 mg per 5 mL, derived from opium , with additional components including 45% alcohol, , , anise oil, and glycerin that contribute to its formulation and mild or flavoring effects. First formulated in the early 1700s as a soothing remedy, it was historically administered to infants and children for , teething pain, and severe , though such practices carried risks of respiratory and dependency due to its content. As a Schedule III controlled substance under U.S. regulations, paregoric has faced scrutiny for abuse potential, notably in mid-20th-century epidemics where it served as an illicit opium source, leading to restricted dispensing and replacement by non-opioid alternatives. Despite never receiving formal FDA approval as a pre-1938 drug, it remains available in limited contexts for refractory cases under prescription.

Composition and Pharmacology

Chemical Composition

Paregoric, also known as camphorated of , is an oral liquid formulation standardized by the to contain the equivalent of 0.4 mg of anhydrous per milliliter, primarily derived from powdered . This content equates to 2 mg per 5 mL dose, with the providing the primary active alkaloids. The preparation includes powdered at approximately 4% concentration (yielding 0.04% ), along with excipients such as 20 mg of , 20 mg of , and 0.02 of oil per 5 . These components are solubilized in an ethanol base comprising about 38.5% per 5 mL serving. In contrast to opium tincture (laudanum), which is standardized to 10 mg of per milliliter, paregoric's formulation is diluted by a factor of 25, reflecting its design for controlled oral dosing. This lower potency distinguishes it from the more concentrated tincture while maintaining as the core ingredient.

Mechanism of Action

Paregoric's antidiarrheal effects stem primarily from its opium-derived alkaloids, especially , which act as agonists at mu-opioid receptors in the of the . Binding to these peripheral receptors inhibits the release of from myenteric neurons, thereby reducing peristaltic activity, prolonging intestinal transit time, increasing non-propulsive segmental contractions, and decreasing and fluid secretion into the gut lumen. This localized action on gut and secretion underlies its therapeutic utility without relying heavily on penetration for primary indications. Opioid components in paregoric also exert central effects by crossing the blood-brain barrier to activate mu-opioid receptors in the , suppressing the and contributing to antitussive properties. Secondary ingredients, such as and oil, provide complementary actions: offers mild local antitussive and antispasmodic effects, while oil's volatile compounds support expectorant activity by promoting mucus clearance. Oral absorption of from paregoric is variable and subject to extensive first-pass hepatic metabolism, resulting in limited systemic that preserves enteric effects while minimizing central compared to higher-dose opioids.

Historical Development

Origins and Pre-Modern Use

The term paregoric derives from the Greek parēgorikos, meaning "soothing" or "consoling," originally referring to persuasive or consolatory speech before evolving to describe pain-relieving or palliative medicines. This nomenclature aligns with the empirical application of opium-derived remedies in ancient Greek and Roman medicine, where extracts from Papaver somniferum were used to treat dysentery and other bowel disorders by observably reducing intestinal spasms and motility. Physicians such as Hippocrates prescribed poppy juice (meconium) for its narcotic and regulatory effects on the gut, while Galen incorporated opium into theriacs and other compounds for enteritic conditions, including diarrhea, capitalizing on its constipating properties to curb excessive evacuations. These uses stemmed from direct observations of opium's capacity to diminish stool frequency and volume, providing symptomatic relief in eras lacking etiological understandings of infectious diarrheas. In , particularly the , opium-infused patent medicines formalized these ancient practices into accessible remedies amid rampant diarrheal mortality, which claimed up to 20-30% of infants annually due to poor and absent rehydration therapies. , patented circa 1721 by London Thomas Godfrey, exemplified this shift; it combined tincture with sassafras, caraway, and sweeteners to soothe infant , teething distress, and dehydrating gastroenteritis, marketed as a "cordial" to calm "gripe" pains and fluxes. Such preparations were empirically prized for halting and thereby conserving fluids, averting in vulnerable patients—a mechanistic benefit inferred from clinical outcomes rather than controlled trials, as opium visibly prolonged gut transit and lowered immediate fatality risks from unchecked losses. Pre-antibiotic reliance on these agents underscored their role in bridging survival gaps for cholera-like epidemics and endemic dysenteries, though overdosing risks tempered their ubiquity.

Nineteenth-Century Applications

In the nineteenth century, paregoric emerged as a key for severe diarrheal conditions amid recurrent pandemics, which afflicted and from the 1830s through the 1860s, claiming millions of lives through unchecked fluid loss and . Opium preparations like paregoric were staples in medical kits, including those of the U.S. during the 1866 outbreak in the western territories, where they were deployed to mitigate intestinal cramps and excessive evacuations when causal interventions such as improvements or rehydration were rudimentary or inaccessible. By suppressing via morphine's action on mu-opioid receptors, paregoric offered tangible relief grounded in observable reductions in stool output, empirically preserving lives in resource-scarce settings despite the absence of bacteriological understanding of Vibrio cholerae. Its adoption extended to household medicine cabinets as an over-the-counter remedy, particularly for pediatric applications targeting "summer complaint"—a seasonal of linked to contaminated , heat, and practices that peaked annually in urban areas, often resulting in high mortality rates among children under two. Physicians prescribed it routinely for teething-related and diarrheal episodes, valuing its dual and antimotility effects to quiet fretful infants and stabilize , with formulations diluted for safety in young patients. Sales proliferated through proprietary vendors and apothecaries, reflecting broad empirical trust in its efficacy even as isolated reports of began surfacing among habitual users by the century's latter decades. Medical formularies increasingly standardized paregoric's preparation, integrating it into professional compendia that balanced its proven benefits against admonitions for precise dosing to avert respiratory or tolerance. This consensus highlighted its role as a pragmatic tool in an era of limited alternatives, prioritizing causal control of symptoms over speculative etiologies like .

Twentieth-Century Evolution and Challenges

In the early twentieth century, paregoric maintained its role as a primary treatment for , especially in pediatric cases, due to the scarcity of effective alternatives before widespread use. The of 1914 imposed federal oversight on opium-containing preparations, mandating registration for handlers and prescriptions for dispensing quantities exceeding exempt limits, which curtailed over-the-counter availability while permitting continued medical prescriptions to address legitimate therapeutic needs amid rising awareness of risks. This regulatory shift reflected causal pressures from international treaties and domestic concerns over proliferation, yet paregoric's diluted formulation allowed it to evade the strictest prohibitions initially applied to purer opiates. Abuse of paregoric escalated in the mid-twentieth century, particularly during the 1950s and 1960s in urban centers like , where socioeconomic disruptions and supply constraints drove substitution with the more accessible elixir. In , no paregoric abusers were recorded among 1,267 narcotics arrests in 1955, but numbers climbed to 10 by 1959 and peaked at 713 out of 994 narcotics users by 1963, representing over 70% among illicit consumers. This surge, often involving high-volume consumption to extract equivalents, correlated with post-World War II urban poverty and black-market dynamics, prompting health authorities to document associated health sequelae like and from adulterated use. Following , paregoric's prominence waned as synthetic antidiarrheals, such as diphenoxylate introduced in the , and improved sanitation reduced demand for opium-based remedies in refractory diarrhea cases. While antibiotics curbed infectious etiologies, these pharmaceutical advances offered targeted efficacy without narcotic risks, leading to paregoric's marginalization in standard formularies despite retention for select unresponsive conditions. Regulatory responses to abuse epidemics, including enhanced monitoring under evolving narcotic laws, further constrained distribution, balancing access preservation against documented dependency patterns.

Clinical Uses and Efficacy

Primary Indications

Paregoric is indicated for the of acute nonspecific in adults and older children, where it addresses hypermotility to reduce stool frequency and fluid loss. This application targets conditions such as fulminant or severe diarrheal episodes not attributable to specific infectious pathogens. Historically, paregoric was employed in pediatric populations for the relief of severe infantile , discomfort, and associated gastrointestinal distress, including , dating back to widespread 18th- and 19th-century use as a remedy. Such applications in neonates and young infants are now contraindicated owing to risks from its and components. ![Old bottle of Paregoric, circa 1940s][float-right]

Dosage and Administration

Paregoric is administered orally as a , typically measured using a calibrated dropper or to ensure accuracy. The standard adult dosage for relief is 5 to 10 mL (equivalent to 1 to 2 teaspoons) administered 1 to 4 times daily, or as directed by a , with adjustments based on symptom response and not exceeding recommended limits to minimize risks of accumulation. For pediatric patients, dosing is weight-based at 0.25 to 0.5 mL per kg of body weight per dose, given 1 to 4 times daily, with strict adherence to age and weight thresholds—particularly avoiding use in neonates under 2 weeks or premature infants without specialist oversight due to heightened respiratory depression risks from its morphine content (approximately 2 mg per 5 mL). In neonates, lower initial doses of 0.1 mL/kg or 2 drops/kg with feedings every 3 to 4 hours may be used under medical supervision, titrated cautiously. Critical administration precautions include verifying the product's concentration to prevent errors from confusing paregoric (0.4 mg/mL ) with undiluted opium (10 mg/mL ), a 25-fold difference that has led to overdoses; dilution or should never be assumed without explicit labeling confirmation. Store the preparation in a tightly closed at controlled , protected from light, to maintain stability and prevent degradation of active alkaloids.

Evidence of Effectiveness

Paregoric's antidiarrheal efficacy derives from its component, a μ-opioid receptor agonist that acts peripherally on enteric neurons in the to inhibit release, suppress , reduce fluid secretion, and enhance , thereby prolonging transit time and solidifying stool consistency. This direct agonism at gut-level receptors—independent of central effects—underpins its targeted control of hypermotility in diarrheal states, outperforming non-opioid agents like in cases of severe secretory or motility-driven diarrhea where peripheral receptor modulation is required. Pharmacological studies on , including derivatives, consistently demonstrate dose-dependent reductions in intestinal propulsion and secretion, with low systemic minimizing broader risks while maximizing local therapeutic action. Historical application in 19th-century diarrheal outbreaks, including epidemics, positioned paregoric as a primary symptomatic , empirically validating its role in mitigating fluid loss and cramps when antisecretory or options were unavailable. Widespread adoption as a household remedy for acute and chronic reflects observed clinical utility prior to modern protocols, though pre-20th-century data lack randomized controls and instead rely on observational outcomes from medical formularies and practitioner reports. Prospective clinical trials on paregoric remain limited owing to regulatory restrictions and ethical barriers against opioid experimentation in uncomplicated , yet comparative evaluations affirm equivalence to other antidiarrheals like diphenoxylate in symptom abatement. In refractory chronic , such as post-surgical , anecdotal and small-cohort experiences highlight rapid normalization, with user aggregates reporting 93% positive outcomes (average rating 9.7/10 across 12 reviews) for sustained control unattainable by placebo or alone. These align with causal evidence of superiority in opioid-sensitive pathologies, rendering paregoric effective for targeted, severe indications but superfluous for self-limiting mild cases responsive to supportive care.

Safety and Risks

Adverse Effects and Side Effects

Paregoric, containing approximately 2 mg of anhydrous morphine per 5 mL dose, commonly produces gastrointestinal adverse effects due to opioid-mediated suppression of , including , , , and abdominal bloating. These effects arise from prolonged intestinal transit time and reduced secretions, with being particularly prevalent during extended use as the drug delays fecal passage. Central nervous system side effects, observed more frequently in ambulatory patients or at doses exceeding therapeutic recommendations, encompass drowsiness, , lightheadedness, and . These result from the central actions of its opium-derived alkaloids, though the preparation's dilute content (equivalent to 0.4 mg anhydrous morphine per mL) and inclusion of emetic limit pronounced euphoria or psychotropic effects under standard dosing. Additional predictable reactions stem from non-opioid components, such as allergic responses to oil manifesting as or urticaria, and ethanol-related in alcohol-sensitive individuals, potentially exacerbating or causing mild . and glycerin may contribute to minor upset stomach in susceptible users, while camphor's antitussive properties rarely induce transient respiratory at therapeutic levels.

Overdose and Addiction Potential

Overdose from paregoric ingestion manifests primarily through opioid-mediated and respiratory depression, including symptoms such as pinpoint pupils, , slowed breathing, drowsiness progressing to , and potentially fatal if untreated. These effects arise dose-dependently from the morphine alkaloid content (approximately 0.4 mg/mL in standard formulations), exacerbated by concurrent factors like alcohol or other sedatives. Acute management involves supportive care, including airway protection and administration of as an to reverse respiratory depression, with repeated dosing potentially required due to paregoric's sustained-release properties from its base. Addiction potential in therapeutic contexts remains low for short-term use in treating acute , attributable to the dilute opioid concentration, presence of aversive excipients like and high content that limit euphoric appeal, and typical dosing regimens (5-10 mL daily for adults) that avoid rapid escalation to dependence. However, chronic or supratherapeutic oral use fosters to antidiarrheal and effects via mu-opioid receptor downregulation, often necessitating discontinuation or rotation to non-opioid alternatives like to prevent escalating doses and symptoms such as abdominal cramps and . Historical patterns of abuse, particularly intravenous injection to concentrate the yield, have demonstrated heightened dependency risks alongside unique non- toxicities; in from 1956-1965, paregoric accounted for up to 72% of identified users by 1963, driven by its availability as a substitute. Such misuse introduced insoluble excipients (e.g., talc-like particles from formulation) into circulation, causing pulmonary foreign body granulomas, , and vascular occlusion in abusers, as documented in case series of intravenous paregoric users exhibiting biopsy-confirmed and elevated pulmonary artery pressures. These sequelae underscore causality from particulate rather than alone, with manifesting as severe withdrawal upon cessation, though overall abuse incidence declined post-1970 federal scheduling due to restricted access.

Historical Pediatric Controversies

In the nineteenth century, paregoric and analogous opium-based soothing syrups were commonly administered to infants to alleviate , discomfort, and crying, often resulting in overuse that precipitated and overdose fatalities. These patent medicines, including preparations akin to paregoric containing or tincture, were implicated in substantial , with historical analyses attributing numerous deaths to unchecked dosing by caregivers seeking to quiet fussy babies rather than addressing underlying causes. Such widespread misuse fueled public outcry and , exemplified by exposés on products like , which contained high levels of and contributed to the momentum for regulatory reform culminating in the of 1906, mandating disclosure of habit-forming ingredients in medications. Despite these risks, empirical observations from the era indicated paregoric's utility in managing severe infantile , where its component reduced intestinal motility and stool frequency, plausibly averting dehydration-related deaths in an age before oral rehydration therapies. Historical medical texts and practice documented lower mortality in outbreaks when preparations were judiciously employed for symptomatic control, underscoring a causal benefit in life-threatening gastrointestinal crises over non- alternatives available at the time. However, this efficacy was overshadowed by dependency issues in routine "quieting" applications, where chronic administration fostered tolerance and withdrawal symptoms upon cessation, establishing a direct link between prolonged exposure and patterns observed in clinical case series. Twentieth-century pediatric debates further highlighted these tensions, particularly in treating neonatal abstinence syndrome () from maternal use, where paregoric reduced mortality from over 90% in untreated cases to below 33% through symptom suppression, yet invited criticism for perpetuating opioid exposure in vulnerable newborns. Verified harms included not only respiratory depression but also excipient-related toxicities, such as those from paregoric's 44-46% content causing metabolic disturbances and inducing seizures, though contemporary contraindications emphasize benzyl alcohol's role in "gasping syndrome" fatalities among neonates. These historical patterns—balancing acute diarrheal salvage against chronic quieting perils—inform modern aversion to paregoric in , prioritizing safer interventions devoid of such multifaceted risks.

United States Regulatory History

Paregoric, a camphorated tincture of opium containing approximately 2 mg of morphine per 5 mL, was widely available over-the-counter in the prior to federal narcotic regulations, marketed as a for treating diarrhea, colic, and teething pain in infants. The , enacted on December 17, 1914, marked the first significant federal intervention by imposing registration, taxation, and record-keeping requirements on handlers of opium and its derivatives, including preparations like paregoric exceeding exempt thresholds. This legislation responded to growing concerns over opium addiction and international obligations, effectively curtailing non-prescription sales and shifting distribution to require oversight for medical purposes, though enforcement initially focused on prohibiting recreational use rather than outright bans on therapeutic applications. Subsequent tightening occurred amid rising abuse reports, particularly in the mid-20th century. By the and , paregoric emerged as a substitute for in regions like , where it accounted for over 70% of users among arrestees by 1963, prompting calls for stricter controls to curb diversion while preserving access for legitimate treatment. The of 1970, part of the Comprehensive Drug Abuse Prevention and Control Act signed on October 27, 1970, classified paregoric as a Schedule III (DEA code 9330 for opium tinctures) based on its moderate abuse potential relative to higher schedules, mandating prescriptions, limiting refills to five within six months, and subjecting it to federal tracking. This scheduling reflected empirical data on dependency risks but imposed administrative burdens that some argued unnecessarily restricted an established remedy with documented efficacy against severe diarrhea. In the 2010s, the Food and Drug Administration intensified scrutiny under its unapproved drugs initiative, targeting products lacking New Drug Applications despite historical use. Paregoric, lacking FDA approval for safety and efficacy labeling, saw commercial formulations withdrawn or reformulated, with manufacturers facing compliance pressures; however, state-licensed compounding pharmacies continue to produce it under prescription as a grandfathered preparation. State-level pharmacy codes further enforced restrictions, such as Pennsylvania's regulation prohibiting sales without a practitioner's order, exemplifying how localized rules addressed diversion amid federal scheduling. These measures prioritized abuse prevention data over unhindered access, occasionally limiting availability of what proponents viewed as a viable treatment option in resource-poor or emergency settings. In the , paregoric is classified as a Schedule III under the , administered by the (), which mandates a valid prescription for dispensing and imposes strict record-keeping and security requirements on pharmacies and manufacturers. Compounding of paregoric is permitted under federal guidelines but subject to DEA oversight, including limits on opium-derived ingredients to curb diversion risks, with no exemptions for over-the-counter sales since the 1970 Comprehensive Drug Abuse Prevention and Control Act amendments. As of 2025, no federal deregulations have occurred post-2020, reflecting broader opioid crisis responses that prioritize misuse prevention through enhanced monitoring, though paregoric's dilute formulation (approximately 2 mg anhydrous morphine per 5 mL) distinguishes it from higher-potency synthetics targeted in recent scheduling actions. Internationally, paregoric's status is governed by the 1961 United Nations Single Convention on Narcotic Drugs, which categorizes opium tinctures as controlled narcotic preparations requiring national licensing for production, import, export, and distribution to ensure medical and scientific use while limiting abuse potential. In the European Union, it falls under stringent opioid regulations harmonized via the European Medicines Agency and national agencies, typically restricting it to prescription-only status with quotas and import certifications, as seen in member states enforcing the convention's schedules without routine over-the-counter availability. In contrast, some developing nations with high diarrhea prevalence, such as Brazil, permit its medical use under local pharmacopeias for antidiarrheal treatment, often compounded locally and studied for safety in resource-limited settings, though subject to national narcotic controls. Global enforcement emphasizes traceability amid the opioid epidemic, with no widespread deregulations reported since 2020, prioritizing access barriers over potency-based exemptions.

Modern Context and Alternatives

Decline in Contemporary Use

The use of paregoric has declined markedly since the 1970s, coinciding with the development of non-opioid medications that offer comparable efficacy with reduced risks of dependence and toxicity. By the early , consensus regarded paregoric as an outdated option, seldom prescribed to its opioid content and associated complications, including potential for and adverse effects from excipients such as and . Key factors in this shift include regulatory controls classifying paregoric as a Schedule V , which impose dispensing restrictions and heighten oversight, alongside growing awareness of neonatal abstinence syndrome risks from maternal exposure and the irritant properties of its non-opioid components leading to toxicity in vulnerable populations. Although retained in pharmacopeias for rare refractory cases, risk-benefit evaluations prioritize alternatives, resulting in minimal contemporary utilization as of 2024. By 2025, branded paregoric has been discontinued since 2011, with availability limited to compounded generics in select settings, underscoring its transition from routine therapy to an exceptional intervention.

Safer Modern Alternatives

, marketed as Imodium, represents a primary modern alternative to paregoric for managing mild to moderate acute in adults, functioning as a peripherally restricted mu-opioid receptor agonist that inhibits intestinal and secretion without significant penetration due to its high lipophilicity and efflux. Clinical evaluations confirm its efficacy in reducing stool frequency and volume, often outperforming and matching or exceeding that of traditional opiates like in nonspecific , while exhibiting a superior profile at therapeutic doses of 4-16 mg daily, with minimal risk of , , or dependence. However, high-dose exceeding 70 mg daily can induce cardiac arrhythmias via blockade, prompting FDA packaging restrictions in 2019 to curb misuse. Diphenoxylate, formulated with atropine as Lomotil, offers a synthetic analog more akin to paregoric's mechanism, combining effects from with synergy to reduce and deter abuse through atropine-induced toxicity at supratherapeutic doses; typical dosing is 5 mg diphenoxylate four times daily. Studies in chronic patients show it reduces stool weight by approximately 44% and frequency by 50%, with lower systemic absorption and potential compared to morphine-containing preparations like paregoric, though it carries risks of side effects such as dry mouth and . For severe or refractory hypermotility, such as in or , opium tincture—a concentrated form without paregoric's —may be used when or diphenoxylate prove inadequate, delivering higher morphine equivalence (10 mg/mL) for potent antisecretory and antimotility action; empirical data indicate remain causally superior in such niches, particularly for alcohol-tolerant adults where tolerance mitigates respiratory risks, though guidelines emphasize rehydration, correction, and etiology-specific interventions like antibiotics over routine opioid use to avoid prolonging bacterial infections. Regulatory caution has diminished paregoric's role, favoring these alternatives' reduced CNS liability despite opioids' enduring mechanistic edge in extreme cases.

References

  1. [1]
    Paregoric: MedlinePlus Drug Information
    Jun 20, 2024 · Paregoric is used to relieve diarrhea. It decreases stomach and intestinal movement in the digestive system.
  2. [2]
    Label: PAREGORIC liquid - DailyMed - NIH
    Paregoric, USP 2 mg*/5 mL, *each 5 mL contains 2 mg of anhydrous morphine (from opium tincture); alcohol 45% and is available in 16 fl. oz (473 mL) bottles.
  3. [3]
    Paregoric - an overview | ScienceDirect Topics
    Paregoric is a mixture of opium powder (anhydrous morphine, 0.4 mg/mL) and ethanol. Other ingredients include benzoic acid, camphor, and anise oil. Its main ...
  4. [4]
    Medication Errors : Nursing2025 - LWW
    First formulated in the early 1700s, paregoric (anhydrous morphine 2 mg per 5 mL, alcohol 47%) has never been FDA-approved but it remained on the U.S. market ...Missing: regulation | Show results with:regulation
  5. [5]
    Lethal Lullabies: A History of Opium Use in Infants - PubMed
    Jul 10, 2015 · Poppy extract accompanied the human infant for more than 3 millenia. Motives for its use included excessive crying, suspected pain, and diarrhea.
  6. [6]
    The abuse of paregoric in Detroit, Michigan (1956-1965)
    ... ingredients are benzoic acid, camphor, and anise oil. The average adult dose is 4 ml by mouth which corresponds to 16 mg of opium, or 1.6 mg of morphine ...Missing: composition | Show results with:composition
  7. [7]
    Characteristics and Sequelae of Paregoric Abuse - ACP Journals
    At the zenith (1963) of its use as a narcotic in this period, paregoric claimed 713 of. 994 narcotics users. Since at present this medical oddity is again ...
  8. [8]
    Pre-1938 Drugs Not Approved by FDA - CompoundingToday.com
    Technically, these products have never been approved by the FDA and do not appear in the "Orange Book" because they are not approved drug products with ...<|control11|><|separator|>
  9. [9]
    Opium Preparations Monograph for Professionals - Drugs.com
    Oct 10, 2024 · Paregoric contains 2 mg of anhydrous morphine (usually as powdered opium, or as opium or opium tincture), 0.02 mL of anise oil, 20 mg of benzoic ...Missing: composition | Show results with:composition
  10. [10]
    Recurring Confusion Between Opium Tincture and Paregoric
    Jun 1, 2003 · Paregoric has just 0.4 mg/mL of morphine, whereas opium tincture contains 10 mg/mL?a 25-fold difference! This is a potentially dangerous situation that invites ...Missing: chemical composition
  11. [11]
    Opium Tincture | Drug Lookup | American Academy of Pediatrics
    Opium tincture is 25 times more concentrated than paregoric; each undiluted mL of opium tincture contains the equivalent of morphine 10 mg/mL.
  12. [12]
    Paregoric dosing, indications, interactions, adverse effects, and more
    Indicated for treatment of diarrhea. 5 -10 mL PO qDay-q6hr or as directed by a physician. Dosage Modifications: Renal impairment, Hepatic impairment.
  13. [13]
    Opioid receptors in the gastrointestinal tract - PMC - PubMed Central
    When released, opioid peptides activate opioid receptors on the enteric circuitry controlling motility and secretion. As a result, inhibition of gastric ...Missing: paregoric | Show results with:paregoric
  14. [14]
    Morphine: Uses, Interactions, Mechanism of Action | DrugBank Online
    Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, ...
  15. [15]
    Pharmacological analysis of paregoric elixir and its constituents
    Nov 1, 2007 · Here, we investigated the pharmacological actions and some of the mechanisms of action of paregoric elixir and compared its action with some of
  16. [16]
    Paregoric (camphorated tincture of opium) - Davis's Drug Guide
    Paregoric contains 0.4 mg per mL of morphine, whereas opium tincture contains 10 mg per mL of morphine. PO Administer with food or meals if GI irritation occurs ...Missing: formulation | Show results with:formulation
  17. [17]
    Paregoric - Etymology, Origin & Meaning
    Originating from Greek paregorikos, meaning "soothing," this word's meaning evolved from "assuaging pain" (1680s) to "medicine that soothes pain" (1704).
  18. [18]
    PAREGORIC Definition & Meaning - Merriam-Webster
    The meaning of PAREGORIC is camphorated tincture of opium used especially to relieve pain.<|separator|>
  19. [19]
    Reciprocal Evolution of Opiate Science from Medical and Cultural ...
    Opium usage in ancient cultures is well documented, as is its major extract morphine. The presence of endogenous opiate alkaloids and opioid peptides in animals ...Missing: paregoric | Show results with:paregoric
  20. [20]
    the history of opium and some of its preparations and alkaloids
    From there it was carried to Greece at a later period. The name opium is derived from the Greek è7rés ... rations of opium still in use are of antique extraction,.
  21. [21]
    WHAT WERE GODFREY'S CORDIAL AND DALBY'S CARMINATIVE?
    Jun 1, 1970 · Many infants died from opium poisoning in the early 1800's, usually as a result of its surreptitious use by nurses to keep infants under their ...Missing: history | Show results with:history
  22. [22]
    The poor child's nurse | Wellcome Collection
    Oct 12, 2017 · Godfrey's Cordial, based on laudanum and treacle, originated in the 18th century. Its tapered bottle made it recognisable before pictorial ...
  23. [23]
    [PDF] Opioid History with Fentanyl Evolving Trends How We Got Here!
    Opium was introduced into China in the 7th century for medicinal use. • By 1000 AD the Arabic physicians were using opium medically for diarrhea and other ...Missing: pre- | Show results with:pre-
  24. [24]
    Cholera and the Army in the West: Treatment and Control in 1866 ...
    A SIATIC cholera, one of the most dreaded epidemic diseases in 19th century America, affected not only the large cities in the East, but also the small.
  25. [25]
    Paregoric : PH371 - Lancaster Medical Heritage Museum
    Paregoric was used in the 18th, 19th and 20th centuries as a household remedy for diarrhea, as an expectorant and cough medicine, to calm children.Missing: pharmacopeia | Show results with:pharmacopeia
  26. [26]
    Laudanum and Paregoric: History and Compounding Considerations
    This article traces the history of opium, older products and current official products (Opium USP, Powdered Opium USP, Opium Tincture USP, Paregoric USP).Missing: pharmacopeia | Show results with:pharmacopeia
  27. [27]
    A Century of American Narcotic Policy - Treating Drug Problems
    American narcotic policy has been highly variable, having passed through at least four major stages during the past 100 years.Missing: paregoric | Show results with:paregoric
  28. [28]
    [PDF] Milestones of Drug Regulation in the United States - FDA
    Jun 30, 2025 · Provisions include measures to accelerate review of devices, regulate advertising of unapproved uses of approved drugs and devices, and regulate.Missing: paregoric | Show results with:paregoric
  29. [29]
    PAREGORIC FOUND ADDICT PROBLEM - The New York Times
    They reported that in 1955 there were no known paregoric addicts in Detroit. In 1959 there were only 10, but, by the end of 1963, the number had risen to 713.Missing: abuse epidemic 1950s 1960s
  30. [30]
    Characteristics and Sequelae of Paregoric Abuse - ACP Journals
    Dec 1, 2008 · At the zenith (1963) of its use as a narcotic in this period, paregoric claimed 713 of 994 narcotics users. Since at present this medical oddity ...
  31. [31]
    The Epidemic of Neonatal Abstinence Syndrome, Historical ...
    Feb 21, 2018 · By 1939, meperidine, the first synthetic opioid, was created; this was followed by the synthesis of methadone in 1946 (2, 10). Due to a ...
  32. [32]
    Paregoric, USP - DailyMed
    Paregoric is useful for the treatment of diarrhea. CONTRAINDICATIONS Hypersensitivity to morphine. Because of its stimulating effect on the spinal cord, ...Missing: pharmacopeia | Show results with:pharmacopeia
  33. [33]
    Paregoric - an overview | ScienceDirect Topics
    Paregoric is a mixture of opium powder (anhydrous morphine, 0.4mg/mL) and ethanol. Other ingredients include benzoic acid, camphor, and anise oil. Its main ...Missing: composition | Show results with:composition
  34. [34]
    The Use of Folk Remedies Among Children in an Urban Black ...
    Mar 1, 2005 · Two of the caregivers interviewed were familiar with the use of paregoric (tincture of opium) to treat colic. Its actions of decreasing gastric ...
  35. [35]
    Paregoric (Anhydrous Morphine): Side Effects, Uses ... - RxList
    Alcohol 45 percent, anise oil, benzoic acid, glycerin, and purified water. Uses for Paregoric. Paregoric (anhydrous morphine) is useful for the treatment of ...Drug Description · Dosage · Side Effects · Precautions
  36. [36]
    7 Action of opiates on gastrointestinal function - ScienceDirect.com
    Most opiates that have a selective or predominant μ agonist activity inhibit gastric motility and delay gastric emptying by acting centrally; δ and κ agonists ...Missing: paregoric | Show results with:paregoric
  37. [37]
    Travelers' Diarrhea - JAMA Network
    diarrhea of all types. Natural opiates (paregoric, deodor¬ ized tincture of opium, and codeine) have long been used to control diarrhea and cramps.Missing: historical epidemics
  38. [38]
    Paregoric | Pain Relief, Opiate-Based & Antidiarrheal - Britannica
    Paregoric, which decreases movement of the stomach and intestinal muscles, is made from opium tincture (laudanum) or from powdered opium and includes anise oil, ...Missing: composition | Show results with:composition
  39. [39]
    Evaluation of an Antidiarrheal Agent: Diphenoxylate Hydrochloride
    Sep 11, 2020 · of camphorated tincture of opium (Paregoric). Diphenoxylate has proven to be a useful adjunc- tive drug in the treatment of many patients suffer ...
  40. [40]
  41. [41]
    Opioid overdose - World Health Organization (WHO)
    Aug 29, 2025 · Opioids are commonly used for the treatment of pain, and include medicines such as morphine, fentanyl and tramadol. Their non-medical use, ...Missing: paregoric | Show results with:paregoric
  42. [42]
    Opioid Tolerance Development: A Pharmacokinetic ...
    Long-term use of opioids can be problematic due to the rapid development of profound tolerance to the analgesic effects coupled with slow development of ...Missing: paregoric | Show results with:paregoric
  43. [43]
    Infections in Paregoric Addicts - JAMA Network
    Its use as an illegal opium source has developed within the last four years (Table 1). Paregoric is a hydroalcoholic solution containing not more than 129.6 mg ...
  44. [44]
    Pulmonary hypertension and foreign body granulomas in ...
    In this report we confirm the presence of pulmonary hypertension by cardiac catheterization in four intravenous drug abusers with biopsy-documented foreign ...Missing: damage | Show results with:damage
  45. [45]
    Mrs. Winslow's Soothing Syrup - DEA Museum
    Mrs. Winslow's Soothing Syrup was a patent medicine first introduced in the 19th century and marketed to calm small children, clean teeth, freshen breath, and ...Missing: paregoric | Show results with:paregoric
  46. [46]
    Neonatal abstinence syndrome: Historical perspective, current focus ...
    Mortality rate estimates in neonates treated for NAS exceeded 33%, and surpassed 90% for un-treated infants during the late-1800s until the mid-1900s. The focus ...Missing: controversies | Show results with:controversies
  47. [47]
    Neonatal Deaths Associated With Use Of Benzyl Alcohol - CDC
    Toxic effects of benzyl alcohol, including respiratory failure, vasodilation, hypotension, convulsions, and paralysis have been known for years (3-5). However, ...Missing: ethanol | Show results with:ethanol
  48. [48]
    Neonatal Abstinence Syndrome - StatPearls - NCBI Bookshelf - NIH
    [43][45] Paregoric (a drug with anhydrous morphine) and dilute tincture of opium were very popular in the past. However, due to its high alcohol content ...
  49. [49]
    Opium Order Form - DEA Museum
    The Harrison Narcotics Act made it harder to get opium without a prescription from a registered medical professional.Missing: paregoric | Show results with:paregoric
  50. [50]
    [PDF] Controlled Substances - Alphabetical Order
    ... Schedule, "CSCN" = Controlled Substance Code Number. Controlled Substances ... Paregoric, other combination products. Opium extracts. 9610. Y. Opium fluid ...
  51. [51]
    28 Pa. Code § 25.75 - Paregoric | State Regulations - Law.Cornell.Edu
    No pharmacist shall sell, dispense or give away a paregoric except under an oral or written prescription order of a licensed practitioner.Missing: requirement | Show results with:requirement
  52. [52]
    Opioid Analgesics and International Conventions - NCBI - NIH
    The Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol (3) is the principal international treaty regulating the control of opioids.Missing: paregoric | Show results with:paregoric
  53. [53]
    Safety evaluation of Elixir paregorico® in healthy volunteers
    Treatment- emergent adverse events were all transient, resolving without any clinical sequela. In developing countries, including Brazil, the combination of ...<|control11|><|separator|>
  54. [54]
    [PDF] Ensuring Adequate Access for Medical and Scientific Purposes - INCB
    Dec 31, 2024 · These recommendations focused on the availability of narcotic drugs and psychotropic substances, appropriate use, national control sys- tems and ...Missing: paregoric | Show results with:paregoric
  55. [55]
    Neonatal Drug Withdrawal | American Academy of Pediatrics
    Jun 1, 1998 · The use of paregoric has declined because of the known and potential toxic effects of its many ingredients. In addition to morphine, it contains ...
  56. [56]
    Item 70491 - Mabee Drug paregoric preparation, Lubec, ca. 1930
    ... ingredient in Paregoric, opium (the source of morphine), by the pint in various strengths “designed for preparing the tincture by direct dilution ...<|separator|>
  57. [57]
    Safety and efficacy of loperamide - PubMed
    Loperamide is a safe and effective antidiarrheal for the treatment of acute diarrhea. Efficacy data suggest that loperamide is more effective than the ...Missing: paregoric | Show results with:paregoric
  58. [58]
    Loperamide - StatPearls - NCBI Bookshelf - NIH
    Feb 28, 2024 · Loperamide is an FDA-approved synthetic phenylpiperidine opioid with high lipophilicity and is a medication used to treat various forms of diarrhea.Missing: paregoric | Show results with:paregoric
  59. [59]
    A New Antidiarrheal Agent in the Treatment of Chronic Diarrhea
    No other side effects attributable to the drug were observed. Loperamide has been found to be a safe and effective agent for the treatment of chronic diarrhea.
  60. [60]
    FDA limits packaging for anti-diarrhea medicine loperamide ...
    Sep 20, 2019 · It is safe at approved doses, but when much higher than recommended doses are taken, it can lead to serious problems, including severe heart ...Missing: paregoric | Show results with:paregoric
  61. [61]
    Diphenoxylate and Atropine - StatPearls - NCBI Bookshelf - NIH
    May 1, 2024 · Diphenoxylate and atropine, a medication combination for managing diarrhea, present a valuable therapeutic option for healthcare professionals.Missing: opium tincture
  62. [62]
    Acute effect of diphenoxylate with atropine (Lomotil) in patients with ...
    Our results in 15 patients revealed that Lomotil ther- apy reduced average stool weight and average stool frequency by 44% and 50%, respectively. These results ...
  63. [63]
    Atropine Plus Diphenoxylate - an overview | ScienceDirect Topics
    The most effective antimotility agents are synthetic opiates, diphenoxylate with atropine, (Lomotil), and loperamide (Imodium).
  64. [64]
    [PDF] Opioid Analgesics and the Gastrointestinal Tract
    Note: None of these drugs have received an FDA-approved indication for treating diarrhea. a. Dose conversion for paregoric and opium tincture not included ...
  65. [65]
    Opioids in the Treatment of Chronic Idiopathic Diarrhea in Humans ...
    Generally, studies reported a reduction in stool frequency and an increase in transit time during treatment with the opioid receptor agonists loperamide, ...
  66. [66]
    Infectious Diarrhea - IDSA
    Oct 19, 2017 · These guidelines are intended for use by healthcare professionals who care for children and adults with suspected or confirmed infectious diarrhea.
  67. [67]
    Chemotherapy-Induced Diarrhea: Options for Treatment and ...
    Loperamide, tincture of opium, and octreotide remain the only agents currently recommended by treatment guidelines, because of the lack of data supporting other ...<|control11|><|separator|>